Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system

Blood Transfusion

Volumn 16, Issue 6, 2018, Pages 483-489

  Cicchetti, Americo ^a   Coretti, Silvia ^a   Sacco, Francesco ^a   Rebulla, Paolo ^b   Fiore, Alessandra ^a   Rumi, Filippo ^a   Bidino, Rossella Di ^c   Urbina, Luz I ^c   Refolo, Pietro ^a   Sacchini, Dario ^a   Spagnolo, Antonio G ^a   Midolo, Emanuela ^d   Marano, Giuseppe ^d   Farina, Blandina ^d   Pati, Ilaria ^d   Veropalumbo, Eva ^d   Pupella, Simonetta ^d   Liumbruno, Giancarlo M ^d  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Pathogen reduction technology; Platelet transfusion; Transfusion risks

Indexed keywords

ARTICLE; BUDGET; GAMMA IRRADIATION; HEMATOLOGICAL PROCEDURE; HUMAN; ITALY; PLATELET PATHOGEN REDUCTION; THROMBOCYTE TRANSFUSION; ADULT; COST; DISINFECTION; ECONOMICS; FEMALE; MALE; PROCEDURES; THROMBOCYTE;

ADULT; BLOOD PLATELETS; COSTS AND COST ANALYSIS; DISINFECTION; FEMALE; HUMANS; ITALY; MALE; PLATELET TRANSFUSION;

EID: 85056068335     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2018.0115-18     Document Type: Article

References (75)

1. Bihl F, Castelli D, Marincola F, et al. Transfusion-transmitted infections. J Transl Med 2007; 5: 25.
2. Giampaolo A, Piccinini V, Catalano L, et al. [First haemovigilance Program on adverse reactions and transfusion errors in Italy: 2004/2005 data]. 2005; Rapp. ISTISAN, ISSN 1123-3117; Italian National Institute of Health (ISS). [In Italian].
3. Velati C, Romanò L, Piccinini V, et al. Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey. Blood Transfus 2018; 16: 422-32.
4. Velati C, Romanò L, Fomiatti L, et al. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 2008; 48: 2205-13.
5. Ainley LI, Hewitt PE. Haematology patients and the risk of transfusion transmitted infection. Br J Haematol 2018; 180: 473-83.
6. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013; 163: 303-14.
7. Kleinman S, Cameron C, Custer B, et al. Modeling the Risk of an Emerging Pathogen Entering the Canadian Blood Supply: EMERGING PATHOGEN RISK. Transfusion 2010; 50: 2592-606.
8. Jacobs MR, Lazarus HM, Maitta RW. The Safety of the Blood Supply -Time to Raise the Bar. N Engl J Med 2015; 373: 882.
9. Musso D, Aubry M, Broult J, et al. Zika virus: new emergencies, potential for severe complications, and prevention of transfusion-transmitted Zika fever in the context of cocirculation of arboviruses. Blood Transfus 2017; 15: 272-3.
10. Marano G, Pupella S, Vaglio S, et al. Zika virus and the neverending story of emerging pathogens and transfusion medicine. Blood Transfus 2016; 14: 95-100.
11. Franchini M, Velati C. Blood safety and zoonotic emerging pathogens: now it's the turn of Zika virus! Blood Transfus 2016; 14: 93-4.
12. Marano G, Pupella S, Pati I, et al. Ten years since the last Chikungunya virus outbreak in Italy: history repeats itself. Blood Transfus 2017; 15: 489-90. rl
13. Vamvakas EC. Risk-reduction strategies for platelet transfusion in the United States. The Sci World J 2011; 11: 624-40. S
14. Stramer SL, Linnen JM, Carrick JM, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-66. iz
15. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-99. v
16. Di Minno G, Navarro D, Perno CF, et al. Pathogen reduction/ inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients? Ann Hematol 2017; 96: 1253-70. Se
17. Magron A, Laugier J, Provost P, Boilard E. Pathogen reduction technologies: The pros and cons for platelet transfusion. Platelets 2018; 29: 2-8.
18. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014; 41: 309-25.
19. Drew VJ, Barro L, Seghatchian J, Burnouf T. Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. Blood Transfus 2017; 15: 512-21.
20. Rebulla P, Vaglio S, Beccaria F, et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reductiontechnologies.Transfusion2017;57:1171-83.
21. Rebulla P, Milani S, Grazzini G. Response to "An unbalanced study that lacks power: a caution about IPTAS". Transfusion 2017; 57: 2285-7.
22. Rebulla P. A pathogen reduction clinical trial in retrospect. Blood Transfus 2017; 15: 329-32.
23. Cicchetti A, Marchetti M, Iacopino V, et al.Organizational Models of Hospital Based HTA: Empirical Evidence from Adhophta European Project. Value Health 2015; 18: A560-1.
24. Sampietro-Colom L, Lach K, Pasternack I, et al. Guiding principles for good practices in hospital-based health technology assessment units. Int J Technol Assess Health Care 2015; 31: 457-65.
25. Favaretti C, Cicchetti A, Guarrera G, et al. Health technology assessment in Italy. Int J Technol Assess Health Care 2009; 25 (Suppl 1): 127-33.
26. Cicchetti A, Berrino A, Casini M, et al. Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. Blood Transfus 2016; 14: 287-386.
27. Assasi N, Schwartz L, Tarride JE, et al. Methodological guidance documents for evaluation of ethical considerations in health technology assessment: a systematic review. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 203-20.
28. Bridges JFP, Jones C. Patient based health technology assessment: A vision for the future. Int J Technology Assess Health Care 2007; 23: 30-5.
29. Bastian H. Speaking up for ourselves. The evolution of consumer advocacy in health care. Int J Technol Assess Health Care 1998; 14: 3-23.
30. Catalano L, Piccinini V, Facco G, et al. Rapporti ISTISAN 16/38. Activities of the Italian Blood System (2015). Available at: http://www.centronazionalesangue.it/sites/default/files/16_38_web.pdf. Accessed on 06/04/2018.
31. State-RegionsAgreementof20October2015(Rep.Attin.168/CSR del20/10/2015)Availableat:http://www.centronazionalesangue.it/ sites/default/files/Accordo%20CSR%2020.10.2015_Prezzo%20 unitario%20cessione%20emocomponenti%20plasmaderivati.pdf. Accessed on 06/04/2018.
32. th December, 2015.
33. Li J, de Korte D, Woolum MD, et al. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
34. Janetzko K, Hinz K, Marschner S, et al. Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS. Vox Sang 2009; 97: 234-9.
35. Stivala S, Gobbato S, Infanti L, et al. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica 2017; 102: 1650-60.
36. Taha M, Culibrk B, Kalab M, et al. Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derived Staphylococcus epidermidis in buffy coat platelet concentrates. Vox Sang 2017; 112: 408-16. TI
37. Lozano M, Knutson F, Tardivel R, et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011; 153: 393-401. M
38. Kaplan A, Lindgren B, Marschner S, et al. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days. Transfus Apher Sci 2015; 54: 248-52. © S
39. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015; 109: 343-52.
40. Nussbaumer W, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017; 112: 249-56.
41. Vilariño MD, Castrillo A, Campos A, et al. Assessment of the Clinical Performance of Platelet Concentrates Treated by Pathogen Reduction Technology in Santiago de Compostela. Transfus Med Hemother 2017; 44: 5-9.
42. Garban F, Guyard A, Labussière H, et al. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. JAMA Oncol. 2018; 4: 468-75.
43. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sang 2012; 103: 322-30.
44. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3: CD009072.
45. Estcourt LJ, Malouf R, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2017; 7: CD009072.
46. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102: 302-16.
47. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004; 86: 239-45.
48. Cazenave JP, Isola H, Waller C, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
49. Chavarin P, DePutter C, Boussoulade F, et al. Pathogen inactivation of platelets: organization consequences for platelet transfusion. Transfus Clin Biol 2011; 18: 472-7.
50. Bardiaux L, Vauzou S, Olivier B, et al. Feasibility study for Intercept platelets. Transfus Clin Biol 2016; 23: 212-6. r
51. Van der Meer PF, Couture C, Hervig T, et al. Experiences with semi-routine production of riboflavin and UV-B pathogen-inactivated platelet concentrates in three blood centres. Vox Sang 2017; 112: 9-17. i S
52. Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox San 2017; 112: 47-55 iz
53. Hong H, Xiao W, Lazarus HM, et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2016; 127: 496-502. er
54. Benjamin RJ. Transfusion-related sepsis: a silent epidemic. Blood 2016; 127: 380-1.
55. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. ClinTher 2003; 25: 2464-86.
56. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004; 80: 317-24.
57. Postma MJ, van Hulst M, De Wolf JT, et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005; 15: 379-87.
58. Janssen MP, van der Poel CL, Buskens E, et al. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-65.
59. Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006; 16: 17-30.
60. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-73.
61. Berger K, Bauer M, Schopohl D, et al. Model Calculations to Quantify Clinical and Economic Effects of Pathogen Inactivation in Platelet Concentrates. Onkologie 2013; 36: 53-9.
62. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the Financial Impact of Pathogen Inactivation Technology for Platelet Components: Our Experience: Pathogen Inactivation Financial Impact. Transfusion 2014; 54: 158-68.
63. McCullough J, Goldfinger D, Gorlin J, et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion 2015; 55: 2312-20.
64. Agapova M, Lachert E, Brojer E, et al. Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis. Transfus Med Hemother 2015; 42: 158-65.
65. Gregoire Y, Delage G, Custer B, Germain M. Cost-effectiveness of pathogen reduction. technology for platelets and plasma in Quebec. Vox Sang 2018; 113 (Suppl 1): ABS P-300.
66. Heddle NM, Lane SJ, Sholapur N, et al. Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood products. Vox Sang 2014; 107: 50-9.
67. Saris A, Kerkhoffs J, Norris P, et al. Effect of storage and pathogen reduction on alloimmunization after platelet transfusions. Vox Sang 2018; 113 (Suppl 1): ABS 5A-S37-03.
68. Yonemura S, Doane S, Keil S, et al. Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfus 2017; 15: 357-64
69. Allain JP, Owusu-Ofori AK, Assennato SM, et al. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 2016; 387: 1753-61.
70. Qadri SM, Chen D, Schubert P, et al. Pathogen inactivation by riboflavin and ultraviolet light illumination accelerates the red blood cell storage lesion and promotes eryptosis. Transfusion 2017; 57: 661-73.
71. Cancelas JA, Gottschall JL, Rugg N, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang 2017; 112: 210-8.
72. Tonnetti L, Laughhunn A, Thorp AM, et al. Inactivation of Babesia microti in red blood cells and platelet concentrates. Transfusion 2017; 57: 2404-12.
73. Cancelas JA, Slichter SJ, Rugg N, et al. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage. Transfusion 2017; 57: 1218-25.
74. Laughhunn A, Huang YS, Vanlandingham DL, et al. Inactivation of chikungunya virus in blood components treated with amotosalen/ultraviolet A light or amustaline/glutathione. Transfusion 2018; 58: 748-57.
75. Brixner V, Kiessling AH, Madlener K, et al. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion 2018 Mar 1. doi: 10.1111/trf.14528.